Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
Open accessThe DOI matches its Crossref record; 34 of the 38 references it cites were found in a registry or an index.
Abstract
Expression of the receptor tyrosine kinase c-MET (MET, mesenchymal-epithelial transition factor) in many cancers, and its participation in multiple signal transduction pathways involved in malignant tumor growth, suggest a wide therapeutic potential for MET inhibition in human cancer. Here we describe the discovery and early clinical development of ARQ 197, a novel, selective, non–ATP-competitive inhibitor of MET. Phase I studies demonstrate that ARQ 197 has a predictable pharmacokinetics and favorable safety profile, making it a potentially ideal partner for combination with cytotoxic chemotherapies and targeted anticancer agents. Results from phase I and phase II trials demonstrate preliminary evidence of anticancer activity. New data from a global phase II randomized trial comparing a combination of ARQ 197 plus erlotinib with erlotinib/placebo, in endothelial growth factor receptor inhibitor-naïve patients with locally advanced/metastatic non–small cell lung cancer, demonstrate improvement in progression-free and overall survival with combined therapy. Results were especially pronounced for patients with non–squamous lung cancer histologies, and in particular molecularly defined subgroups including KRAS mutations. These and other data from ARQ 197 clinical trials in hepatocellular, germ-cell, pancreatic (in combination with gemcitabine), and colorectal (in combination with cetuximab and irinotecan) cancers further highlight the potential role of ARQ 197 in existing and emerging anticancer therapeutic regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tivantinib is a selective oral MET inhibitor that has been used in monotherapy and combination therapy for solid tumors, including mCRC [188].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [188]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
Beroukhim, R., Getz, G., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, I., Lee, J. C., Huang, J. H., Alexander, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710052104 · Cited by 1,075
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 818
Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase
Birchmeier, C., & Gherardi, E. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01359-2 · Cited by 597
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
Christensen, J. G., Burrows, J., & Salgia, R. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.09.044 · Cited by 513
Met receptor tyrosine kinase: enhanced signaling through adapter proteins
Furge, K. A., Zhang, Y.-W., & Vande Woude, G. F. (2000) · Oncogene · doi:10.1038/sj.onc.1203859 · Cited by 410
A novel germ line juxtamembrane Met mutation in human gastric cancer
Lee, J.-H., Han, S.-U., Cho, H., Jennings, B., Gerrard, B., Dean, M., Schmidt, L., Zbar, B., & Vande Woude, G. F. (2000) · Oncogene · doi:10.1038/sj.onc.1203874 · Cited by 329
Munshi, N., Jeay, S., Li, Y., Chen, C.-R., France, D. S., Ashwell, M. A., Hill, J., Moussa, M. M., Leggett, D. S., & Li, C. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1173 · Cited by 326
HGF/SF‐met signaling in the control of branching morphogenesis and invasion
Zhang, Y., & Vande Woude, G. F. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10358 · Cited by 307
Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer
Jiang, W. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(98)00019-5 · Cited by 264
The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma
Derksen, P. W. B., de Gorter, D. J. J., Meijer, H. P., Bende, R. J., van Dijk, M., Lokhorst, H. M., Bloem, A. C., Spaargaren, M., & Pals, S. T. (2003) · Leukemia · doi:10.1038/sj.leu.2402875 · Cited by 170
Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Underiner, T. L., Herbertz, T., & Miknyoczki, S. J. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611009010007 · Cited by 149
MET as a target for treatment of chest tumors
Cipriani, N. A., Abidoye, O. O., Vokes, E., & Salgia, R. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2008.06.011 · Cited by 120
Jiang, W. G., Hiscox, S., Parr, C., Martin, T. A., Matsumoto, K., Nakamura, T., & Mansel, R. E. (1999) · PubMed · Cited by 103
Toschi, L., & Jänne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0071 · Cited by 103
Pan, B., Chan, G. K. Y., Chénard, M., Chi, A., Davis, L. J., Deshmukh, S. V., Gibbs, W. W., Gil, S., Hang, G., Hatch, H., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2541 · Cited by 91
Garcia, Á. T., Rosen, L. S., Cunningham, C. C., Nemunaitis, J. J., Li, C., Rulewski, N., Dovholuk, A., Savage, R. E., Chan, T.-C., Bukowksi, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3525 · Cited by 54
Zeng, Z., Weiser, M. R., D’Alessio, M., Grace, A., Shia, J., & Paty, P. B. (2004) · Clinical & Experimental Metastasis · doi:10.1007/s10585-005-1617-4 · Cited by 53
Absence oftpr-metand expression ofc-metin human gastric mucosa and carcinoma
Heideman, D. A. M., Snijders, P. J. F., Bloemena, E., Meijer, C. J. L. M., Offerhaus, G. J. A., Meuwissen, S. G. M., Gerritsen, W. R., & Craanen, M. E. (2001) · The Journal of Pathology · doi:10.1002/path.934 · Cited by 36
Goldberg, J., Demetri, G. D., Choy, E., Rosen, L. S., Pappo, A. S., DuBois, S. G., Geller, J. I., Chai, F., Ferrari, D., & Wagner, A. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.10502 · Cited by 36
Laux, I., Goldman, J., Just, R. G., Brady, K. J., Li, J., Schwartz, B., Savage, R. E., Garmey, E. G., & Rosen, L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3549 · Cited by 27
Self-citationMekhail, T. M., Rich, T., Rosen, L. S., Chai, F., Semic-Suka, Z., Savage, R. E., & Senzer, N. N. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3548 · Cited by 26
Jeay, S., Munshi, N., Hill, J. E., Moussa, M. M., Ashwell, M. A., Leggett, D., & Li, C. (2007) · Cancer Research · Cited by 23
Zucali, P. A., Santoro, A., Rodriguez-Lope, C., Simonelli, M., Camacho, L. H., Senzer, N. N., Bolondi, L., Lamar, M. E., Abbadessa, G., & Schwartz, B. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.4137 · Cited by 17
Self-citationYap, T. A., Frentzas, S., Tunariu, N., Barriuso, J., Harris, D. L., Germuska, M. A., Waghorne, C. G., Li, J., deSouza, N. M., & Bono, J. S. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3523 · Cited by 14
Anderson, K. C., Li, C., Moreau, J. E., Chan, T., & Rosenblatt, M. (2007) · Molecular Cancer Therapeutics · Cited by 10
Borbath, I., Santoro, A., Laethem, J. V., Daniele, B., Cicalese, L., Zeuzem, S., Buggish, P., Bolondi, L., Strosberg, J., & Abbadessa, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.tps215 · Cited by 9
Camacho, L. H., Bendell, J. C., John-Reid, L., Campos, L. T., Jones, S. F., Kazakin, J., Savage, R. E., Schwartz, B. E., Abbadessa, G., & Saleh, M. N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13008 · Cited by 7
Self-citationAdjei, A. A., Sosman, J. A., Dy, G. K., Ma, W., Fetterly, G. J., Skupien, D., Means, J. A., Savage, R. E., Chai, F., & Puzanov, I. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3024 · Cited by 6
Self-citationJARVIS, L. M. (2007) · Chemical & Engineering News · doi:10.1021/cen-v085n034.p015 · Cited by 6
BIOPHARMACEUTICALS Novartis gets preliminary nod for new flu vaccine
JARVIS, L. M. (2007) · Chemical & Engineering News · doi:10.1021/cen-v085n019.p015a · Cited by 4
Yap, T. A., Barriuso, J., Frentzas, S., Riisnaes, R., Clark, J., Dukes, J., Futreal, P. A., Savage, R. E., Chai, F., & Bono, J. S. D. (2008) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(08)72320-6 · Cited by 2
Research works printed but not linked: 12
- Gu X, Wang C, Yu Y et al. Inhibition of HGF/c-Met pathway by ARQ 197: characterization of pharmacodynamic markers in vitro and in vivo. Poster presented at: 2009 AACR Annual Meeting, Denver, CO, April 18, 2009; Abstract 1748.
- Li Y, Chen D, Zhou W et al. Broad spectrum anti-cancer activity of ARQ 197, a highly selective oral c-Met inhibitor, in multiple xenograft models. Poster presented at: 98th AACR Annual Meeting; April 14 -18, 2007, Los Angeles, CA; Poster 2216.
- Savage RE, Zhong C, Hall T et al. In vitro ADME Properties of ARQ-197. Comparison to in vivo data. Poster presented at: 99th AACR Annual Meet- ing, Philadelphia, PA, April 12, 2009; Poster 1291.
- Santoro A, Simonelli M, Zucali P. A Phase Ib safety trial of ARQ 197 in cirrhotic patients with hepatocellular carcinoma (HCC). Poster presented at: American Society of Clinical Oncology Gastrology; 2010; Poster 1961.
- Rosen L, Senzer N, Nemunaitis J et al. Phase 1 dose escalation study and signs of anti-metastatic activity of ARQ 197, a selective c-Met inhibitor. Paper presented at: AACR-NCI-EORTC International Conference, San Francisco, CA, October 22, 2007; Abstract B91.
- Adjei AA, Sosman J, Dy GK et al. A Phase 1 dose-escalation trial of the c-MET inhibitor ARQ 197 administered in combination with sorafenib in adult patients with advanced solid tumors. Poster presented at: American Society of Clinical Oncology meeting, Chicago, IL, June 4 -8, 2010; Poster 3024.
- Goldman J, Rosen L, Laux I et al. Phase I dose escalation trial (ARQ 197- 111) evaluating combination of selective c-Met inhibitor ARQ 197 and er- lotinib. Oral presentation at: IASLC 13th World Conference on Lung Cancer; August 1, 2009; San Francisco, CA, USA; Presentation A6.5.
- Santoro A, Simonelli M, Zucali P et al. Preliminary results from ARQ 197- 144: a phase 1b safety trial evaluating ARQ 197 in cirrhotic patients with hepatocellular carcinoma (HCC). Poster presented at: American Society of Clinical Oncology meeting, Chicago, IL, June 4 -8, 2010; Poster 1961.
- Wagner A, Demetri GD, Choy E et al. Preliminary results from a Phase 2 study of ARQ 197 in patients with microphthalmia transcription factor fam- ily (MiT) associated tumors. Oral presentation to: Connective Tissue On- cology Society, Miami, FL, November 26, 2009. Oral presentation 39313.
- Camacho L, Chen CL, Kazakin J et al. A phase 1b dose-escalation trial evaluating ARQ 197 administered in combination with gemcitabine to pa- tients with advanced solid tumors. Paper presented at: American Society of Clinical Oncology meeting, Chicago, IL, June 4 -8, 2010; Abstract e13008.
- Schiller JH, Akerley WL, Brugger W et al. Results from ARQ 197-209: a global randomized placebo-controlled Phase 2 clinical trial comparing er- lotinib plus ARQ 197 to erlotinib plus placebo in previously treated EGFR- inhibitor naive patients with locally advanced or metastatic non-small cell lung cancer. Paper presented at: American Society of Clinical Oncology meeting oral presentation, Chicago, IL, June 4 -8, 2010; Abstract LBA7502.
- Sequist, 2010, Final results from ARQ 197–209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinb plus placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small cell lung cancer (NSCLC)
Cited by
MET: a promising anticancer therapeutic target
Peters, S., & Adjei, A. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.71 · Cited by 280
Self-citationCytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
Katayama, R., Aoyama, A., Yamori, T., Qi, J., Oh-hara, T., Song, Y., Engelman, J. A., & Fujita, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3256 · Cited by 213
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy
Wen, S., Wang, G., Zhang, Y., Bu, F., Zhang, S., Miller, D. D., Li, W., Ouyang, L., & Wang, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00100 · Cited by 157
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy
Riquelme, I., Saavedra, K., Espinoza, J. A., Weber, H. L., García, P., Nervi, B., Garrido, M., Corvalán, A. H., Roa, J. C., & Bizama, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4990 · Cited by 151
Metadata
- Authors
- Adjei, A. A., Schwartz, B., & Garmey, E.
- Affiliations
- Roswell Park Comprehensive Cancer Center (US)
- Arqule (United States) (US)
- Corresponding author
- Adjei, Alex A.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-05-31
- Volume
- 16
- Issue
- 6
- Pages
- 788-799
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC3228218
- OpenAlex
- W2120107140
- Cited by
- 73
- References
- 38
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 3 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 4 · 2015: 7 · 2014: 12 · 2013: 12 · 2012: 8
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- ARQ 197, MET inhibitors, non-ATP-competitive inhibitors, c-Met, non-small cell lung cancer, KRAS mutation, progression-free survival, hepatocellular carcinoma, germ cell tumors, pancreatic cancer, colorectal cancer, cetuximab, irinotecan, combination chemotherapy, pharmacokinetics, drug safety
- MeSH terms
- Cetuximab, Erlotinib Hydrochloride, Irinotecan, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Dose-Response Relationship, Drug, Enzyme Inhibitors, Humans, Neoplasms, Pyrrolidinones, Quinazolines, Quinolines, Randomized Controlled Trials as Topic, Hepatocyte Growth Factor, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Receptors, Growth Factor, Proto-Oncogene Proteins c-met, Mice, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.